ExAblate Blood Brain Barrier Disruption (BBBD) for Planned Surgery in Suspected Infiltrating Glioma

Glioma Clinical Trial

Official title:

A Study to Evaluate the Safety and Feasibility of Exablate Model 4000 Type-2 to Temporarily Mediate Blood-Brain Barrier Disruption (BBBD) in Patients With Suspected Infiltrating Glioma in the Setting of Planned Surgical Interventions

Clinical Trial Details — Status: Suspended

Administrative data

• NCT number: NCT03322813
• Other study ID #: BT004
• Status: Suspended
• Phase: N/A
• Start date: October 2023
• Est. completion date: December 2024

Study information

• Verified date: August 2022
• Source: InSightec
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is designed to assess the safety and feasibility of using the ExAblate, Type 2 to temporarily disrupt the blood brain barrier in non-enhancing suspected infiltrating glioma. The ExAblate Model 4000 Type-2 is intended for use as a tool to disrupt the BBB.

Description:

This study is a prospective, single-arm, non-randomized, open-label feasibility study to evaluate the safety of focal BBBD using the ExAblate® 4000 Type 2 system. Up to 15 subjects with suspected infiltrating glioma who are scheduled to undergo brain tumor resection may be recruited for the study. Only patients that have a non-enhancing tumor components in a non-eloquent region of the planned standard-of-care resection volume will be eligible. Up to 4 centers may participate in this study.

Recruitment information / eligibility

• Status: Suspended
• Enrollment: 15
• Est. completion date: December 2024
• Est. primary completion date: September 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 21 Years to 85 Years

Eligibility

Inclusion Criteria:

1. Male or Female between 21-85 years of age

2. Able and willing to give informed consent

3. Subjects with suspected infiltrating glioma on pre-operative brain imaging scans including non-enhancing MRI tumor components in non-eloquent regions that are within the planned surgical resection volume

4. Surgical area targeted for ExAblate treatment (i.e. prescribed Region of Treatment) =30 cm3; planned surgical resection volume may exceed the targeted treatment volume

5. Karnofsky Performance Score 70-100

6. Able to communicate sensations during the ExAblate® BBBD procedure

Exclusion Criteria:

1. MRI or clinical findings of:

• Active or chronic infection(s) or inflammatory processes

• Acute or chronic hemorrhages, specifically any lobar microbleeds, and no siderosis, amyloid angiopathy, or macrohemorrhages

• Intracranial thrombosis, vascular malformation, cerebral aneurysm or vasculitis

• Evidence of tumor-related calcification, cyst, or hemorrhage

• Midline shift of >10mm or evidence of subfalcine, uncal, or tonsillar herniation on pre-operative imaging

2. More than 30% of the skull area traversed by the sonication pathway is covered by scars, scalp disorders (e.g., eczema), or atrophy of the scalp

3. Clips, shunts, or any metallic implanted objects in the skull or the brain or the presence of unknown MR unsafe devices anywhere within the body

4. Significant cardiac disease or unstable hemodynamic status

5. Uncontrolled hypertension (systolic > 150 and diastolic BP > 100 on medication)

6. Receiving anticoagulant (e.g. warfarin) or antiplatelet (e.g. aspirin) therapy within one week of focused ultrasound procedure or drugs known to increase risk of hemorrhage (e.g. Avastin) within one month of focused ultrasound procedure

7. History of a liver disease, bleeding disorder, coagulopathy or a history of spontaneous hemorrhage

8. Abnormal coagulation profile (Platelets < 100,000), PT (>14) or PTT (>36), and INR > 1.3

9. Lacunar lesions or evidence of increased risk of bleeding

10. Known cerebral or systemic vasculopathy

11. Significant depression and at potential risk of suicide

12. Known sensitivity/allergy to gadolinium, or other intravascular contrast agents

13. Active seizures despite medication treatment (defined as >1 seizure per month) which could be worsened by disruption of the blood brain barrier

14. Evidence of worsening neurological function

15. Dexamethasone dose = 24mg daily or equivalent steroid dose

16. History of drug or alcohol disorder which have a higher risk for seizures, infection and/or poor executive functioning

17. Positive HIV status, which can lead to increased entry of HIV into the brain parenchyma leading to HIV encephalitis

18. Potential blood-borne infections which can lead to increased entry to brain parenchyma leading to meningitis or brain abscess

19. Any contraindications to MRI scanning, including:

• Large subjects not fitting comfortably into the scanner

• Difficulty lying supine and still for up to 3 hours in the MRI unit or claustrophobia

20. Untreated, uncontrolled sleep apnea

21. Impaired renal function with estimated glomerular filtration rate <30 mL/min/1.73m2

22. Respiratory: chronic pulmonary disorders e.g. severe emphysema, pulmonary vasculitis, or other causes of reduced pulmonary vascular cross-sectional area, patients with a history of drug allergies, asthma or hay fever, and multiple allergies where the benefit/risk of administering Definity® is considered unfavorable by the study physicians in relation to the product labeling for Definity

23. Currently in a clinical trial involving an investigational product or non-approved use of a drug or device

Related Conditions & MeSH terms

• Glioma

Intervention

Device:
• ExAblate 4000 - Type 2
Using ExAblate Model 4000 Type-2 to temporarily disrupt the blood brain barrier in non-enhancing suspected infiltrating glioma undergoing resection

Locations

Country	Name	City	State
United States	University of Maryland Medical System	Baltimore	Maryland

Sponsors (1)

Lead Sponsor	Collaborator
InSightec

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Device and procedure related adverse events	The number and severity of device and BBBD procedure related adverse events will be evaluated.	At the time of the ExAblate MRgFUS procedure
Secondary	Feasibility of BBB disruption	The extent and reversibility of BBB opening will be determined by the degree of contrast enhancement seen on post-procedure MRI with contrast agent	At the time of the ExAblate MRgFUS procedure and 24 hours post-procedure